Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Poland: These 44 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Poland: These 44 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in Poland?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Poland Patent 1,978,015

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Poland?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Poland Patent 2,101,740

Drug Price Trends for ZUBSOLV
ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Poland?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Poland Patent 2,091,918

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Poland?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Poland Patent 2,091,940

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Poland?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Poland Patent 1,988,877

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in Poland?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Poland Patent 1,968,601

VYKAT XR is a drug marketed by Soleno. There are six patents protecting this drug. There has been litigation on patents covering VYKAT XR

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Poland?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Poland Patent 2,120,963

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Poland?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Poland Patent 1,973,545

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Poland?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Poland Patent 2,495,016

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Poland?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Poland Patent 2,107,905

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Poland?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Poland Patent 2,079,445

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Poland?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Poland Patent 2,079,445

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch in Poland?

Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2027
Generic Entry Controlled by: Poland Patent 1,989,182

PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering PRESTALIA

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in Poland?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Poland Patent 1,999,109

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in Poland?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Poland Patent 2,363,392

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can INLYTA (axitinib) generic drug versions launch in Poland?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Poland Patent 2,134,702

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Poland?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Poland Patent 2,007,756

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Poland?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Poland Patent 2,674,428

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Poland?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Poland Patent 3,091,011

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Poland?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Poland Patent 3,327,016

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Poland?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Poland Patent 3,090,730

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Poland?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Poland Patent 4,400,104

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Poland?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Poland Patent 2,164,473

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Poland?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Poland Patent 2,164,467

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Poland?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Poland Patent 2,500,014

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Poland?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Poland Patent 2,164,467

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Poland?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Poland Patent 2,500,014

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in Poland?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Poland Patent 2,526,932

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch in Poland?

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Poland Patent 2,719,378

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Poland?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Poland Patent 2,170,050

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Poland?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Poland Patent 2,081,921

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Poland?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,046,318

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Poland?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,450,035

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Poland?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,046,318

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Poland?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,450,035

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Poland?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,164,844

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Poland?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,754,660

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch in Poland?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Poland Patent 2,016,940

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can TRIFERIC AVNU (ferric pyrophosphate citrate) generic drug versions launch in Poland?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Poland Patent 2,016,940

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Poland?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Poland Patent 2,152,237

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Poland?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Poland Patent 4,218,732

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Poland?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Poland Patent 2,503,005

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Poland?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Poland Patent 2,966,175

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Poland?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Poland Patent 2,049,522

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in Poland?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: Poland Patent 2,182,988

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can MYRBETRIQ (mirabegron) generic drug versions launch in Poland?

Generic name: mirabegron
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2027
Generic Entry Controlled by: Poland Patent 2,216,021

MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering MYRBETRIQ

See drug price trends for MYRBETRIQ.

The generic ingredient in MYRBETRIQ is mirabegron. Additional details are available on the mirabegron profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Poland?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Poland Patent 2,942,065

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Poland?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Poland Patent 2,942,065

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Poland?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Poland Patent 2,222,285

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Poland?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Poland Patent 3,143,992

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Poland?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Poland Patent 3,492,069

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Poland?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Poland Patent 3,895,699

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Poland?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Poland Patent 2,217,610

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Poland?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Poland Patent 2,217,577

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Poland?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Poland Patent 2,217,577

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Poland?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2027
Generic Entry Controlled by: Poland Patent 2,086,940

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Poland?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Poland Patent 2,096,919

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Poland?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Poland Patent 2,225,230

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Poland?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Poland Patent 2,101,777

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Poland?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Poland Patent 3,176,159

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

Poland Branded and Generic Drug Market: Regulatory Opportunities, Patent Risk and Commercial Outlook

Last updated: October 14, 2026

Poland is the largest pharmaceutical market in Central and Eastern Europe and has a predominantly generic prescription base. The market offers volume, manufacturing and localization opportunities, but price regulation, reimbursement controls, procurement concentration, reference pricing and delayed market access constrain margins. Generic companies can enter after EU regulatory exclusivity expires, subject to patent and SPC clearance. Poland has no U.S.-style Paragraph IV system or Orange Book.

What is the size and structure of Poland’s pharmaceutical market?

Poland’s pharmaceutical market is driven by community pharmacy sales, reimbursed prescription medicines, hospital procurement and a large over-the-counter segment. Generics account for most prescription volumes, while originator products retain substantial value share in oncology, immunology, diabetes, neurology and specialty hospital therapies.

Market segment Main commercial characteristics
Reimbursed retail medicines Controlled by national reimbursement lists, price limits and pharmacy substitution
Non-reimbursed prescription drugs More flexible pricing but exposed to generic competition
OTC medicines Strong consumer and pharmacy influence; brand recognition matters
Hospital medicines Tender-driven, price-sensitive and increasingly concentrated in specialty products
Innovative medicines Dependent on Ministry of Health reimbursement decisions and health-technology assessment
Biosimilars Growing opportunity in oncology, immunology and supportive care

The principal domestic and multinational participants include Polpharma, Adamed, Krka, Zentiva, Teva, Sandoz, Viatris, Medana Pharma, Lek-Am, Bayer, Sanofi, Novo Nordisk, AstraZeneca, Pfizer, Roche, Novartis and Johnson & Johnson. The competitive field is fragmented in conventional generics but concentrated in hospital and specialty products.

IQVIA, PEX PharmaSequence and public reimbursement data are the principal sources used by industry participants to track market value, volume, channel sales and product performance. Public sources do not provide a single comprehensive market figure because results vary by inclusion of OTC, hospital products, parallel trade and VAT treatment.[1]

How does Poland regulate branded and generic medicines?

Poland operates within the EU pharmaceutical framework. The main institutions are:

Institution Function
URPL Marketing authorization, pharmacovigilance and medicinal-product registration
GIF Good manufacturing practice, distribution, inspections and pharmacy oversight
Ministry of Health Reimbursement, pricing policy and national pharmaceutical policy
AOTMiT Health-technology assessment and reimbursement recommendations
EMA Centralized EU authorization for qualifying products
European Commission Grants centralized marketing authorizations and manages EU pharmaceutical rules

Generic medicines may use the EU abridged application route under Article 10 of Directive 2001/83/EC. The applicant generally relies on the reference product’s dossier and demonstrates pharmaceutical equivalence and bioequivalence, unless a waiver or another legal basis applies.[2]

Poland accepts products authorized through centralized, decentralized, mutual-recognition and national procedures. A product must obtain a Polish marketing authorization or valid EU authorization before commercial distribution.

What is the FDA status of medicines sold in Poland?

FDA approval is not required for Polish marketing. A product may be sold in Poland if it has a valid EU or Polish authorization and complies with Polish distribution, labeling, pharmacovigilance and reimbursement rules. FDA approval can support global development and manufacturing credibility, but it does not replace URPL, EMA or European Commission requirements.

What is the reimbursement and pricing environment?

Poland’s reimbursement system is governed mainly by the Reimbursement Act of 12 May 2011. The Ministry of Health publishes reimbursement announcements, generally on a two-month cycle. Products are assigned to reimbursement groups, and the reimbursement limit can determine the patient co-payment and commercial viability.[3]

Key commercial controls include:

  • official ex-factory and retail price arrangements;
  • reimbursement groups and common financing limits;
  • maximum wholesale and retail margins;
  • price negotiations with the Ministry of Health;
  • health-technology assessment for many innovative products;
  • payback mechanisms when public reimbursement expenditure exceeds statutory limits;
  • mandatory or strongly encouraged generic substitution in pharmacy practice;
  • hospital tenders and framework purchasing.

A lower list price can improve reimbursement positioning but can also reduce the reference price for an entire product group. Companies therefore assess net price, reimbursement volume, mandatory discounts, tender deductions and payback exposure rather than list price alone.

What opportunities exist in Poland’s reimbursement market?

Opportunities are strongest where a supplier can combine:

  1. a low sustainable price;
  2. reliable supply and local stock;
  3. an eligible reimbursement pathway;
  4. evidence supporting cost-effectiveness;
  5. differentiated dosage forms or delivery systems; and
  6. manufacturing capacity for strategic or shortage-prone medicines.

The Ministry of Health has increased attention to domestic production and supply security. This creates opportunities for local manufacturing, contract manufacturing, active pharmaceutical ingredient sourcing, critical-medicine projects and technology-transfer arrangements.

When do branded drugs lose exclusivity in Poland?

EU exclusivity generally follows the “8+2+1” framework:

Protection General period
Regulatory data exclusivity 8 years
Marketing protection 2 additional years
Possible additional market protection 1 year for a significant new indication
Pediatric extension 6 months, subject to completion of an agreed pediatric investigation plan
Orphan-market exclusivity 10 years, potentially extended to 12 years for pediatric compliance
SPC protection Up to 5 years after patent expiry, with a possible six-month pediatric extension

The eight-year data period generally prevents generic applicants from relying on the reference product’s dossier. The following two-year marketing-protection period can delay commercial placement even after a generic authorization has been granted. The additional one-year period is available only under defined conditions and is not automatic.[4]

Patent expiry depends on the specific compound, formulation, manufacturing process, dosage regimen and jurisdiction. A generic launch assessment must review the basic patent, later-filed patents, SPCs, pediatric extensions, divisional applications, opposition outcomes and national litigation.

What patents protect branded medicines in Poland?

The Polish patent estate for a drug can include:

Patent type Typical subject matter
Compound patent Active pharmaceutical ingredient or molecular class
Salt, polymorph or crystal patent Solid-state form, salt, hydrate or solvate
Formulation patent Release profile, excipients, stabilizers or delivery system
Combination patent Active ingredient combined with another therapy
Method-of-use patent Treatment of a disease, patient population or dosing regimen
Manufacturing patent Synthetic route, purification or intermediate
Device patent Injector, inhaler, cartridge, patch or administration system
SPC Supplementary protection for an authorized medicinal product

The strength of a Polish patent estate depends on claim scope, remaining term, validity under the European Patent Convention, enforceability in Polish courts and the availability of non-infringing alternatives. Formulation and method-of-use patents can delay entry even where the compound patent has expired, but their commercial effect depends on prescribing practice, substitution rules and the ability to design around the claims.

How strong is the patent estate for a generic launch?

A practical freedom-to-operate review should classify each relevant right as:

  • expired;
  • active but commercially irrelevant;
  • vulnerable to invalidity;
  • avoidable through product design;
  • capable of supporting an injunction; or
  • likely to require a negotiated license.

European patents validated in Poland can be challenged through opposition at the European Patent Office within the applicable opposition period, through limitation or revocation mechanisms, and through Polish national proceedings. SPCs may also be contested on validity and entitlement grounds.

Does Poland have Paragraph IV challenges or an Orange Book?

Poland has neither a U.S.-style Paragraph IV certification system nor an Orange Book. Generic applicants do not make a formal Polish Paragraph IV declaration to notify the originator.

Instead, generic entry risk is assessed through:

  • European patent and SPC searches;
  • EPO oppositions;
  • Polish revocation or infringement actions;
  • non-infringement and invalidity opinions;
  • regulatory exclusivity analysis;
  • preliminary-injunction exposure; and
  • settlement or licensing negotiations.

Poland’s patent register and EPO records are more relevant than the FDA Orange Book. The absence of an Orange Book does not eliminate patent risk. It changes the timing, notice and litigation mechanics.

What is the biosimilar opportunity in Poland?

Biosimilars are regulated through the EU pathway and assessed by EMA when the product falls within the centralized procedure. The applicant must demonstrate a high degree of similarity to the reference biologic through analytical, pharmacokinetic, immunogenicity and, where required, clinical evidence.[5]

Poland offers growth potential in:

  • oncology biologics;
  • insulin and diabetes therapies;
  • autoimmune disease;
  • granulocyte colony-stimulating factors;
  • erythropoietins;
  • ophthalmology; and
  • hospital-administered biologics.

Biosimilar uptake is influenced by hospital tenders, reimbursement limits, physician confidence, switching policy, tender continuity and supply reliability. Unlike conventional generics, biosimilars generally require more complex manufacturing, greater analytical investment and stronger pharmacovigilance systems.

Biosimilar patent risk may involve the reference molecule, formulation, manufacturing process, device and method-of-use claims. EU data and market protection also apply, subject to the reference product’s authorization history and applicable exclusivity periods.

What generic entry risks exist in Poland?

Generic launch scenarios generally fall into four categories:

Scenario Commercial timing Main risk
Patent and SPC clear At regulatory expiry and after launch planning Price erosion and rapid substitution
Patent invalidity challenge Before or near expiry Injunction, damages and litigation cost
Design-around launch After regulatory exclusivity, before some secondary patents expire Formulation or method-of-use infringement
Licensed launch Based on negotiated rights Royalty burden and settlement restrictions

The largest risks are secondary patents, pediatric or orphan exclusivity, manufacturing-process claims, preliminary injunctions and reimbursement delays. A product may have regulatory approval but remain commercially blocked by a valid patent or SPC.

What patent litigation affects Poland’s drug market?

Polish patent litigation is product-specific rather than market-wide. Common disputes involve:

  • validity of formulation or dosage patents;
  • infringement by generic products;
  • SPC eligibility;
  • second-medical-use claims;
  • preliminary injunctions before commercial launch;
  • confidential settlement terms;
  • damages or accounts of profits; and
  • cross-border coordination with EPO and other European proceedings.

Settlement agreements may permit a launch before the last patent expiry, but their terms can include delayed-entry dates, supply restrictions, geographic limits, royalty payments and conditions linked to parallel litigation. Competition-law review is relevant where an originator agrees to compensate a generic company for delayed entry.

What licensing deals and manufacturing opportunities exist?

Poland is a significant manufacturing and commercialization base for Central and Eastern Europe. Licensing opportunities include:

  • in-licensing late-stage generic dossiers;
  • out-licensing Polish-developed products;
  • contract manufacturing;
  • API and finished-dose supply;
  • co-development of complex generics;
  • biosimilar commercialization;
  • local packaging and serialization;
  • hospital tender partnerships; and
  • distribution agreements covering the Baltic, Balkan and Central European regions.

Local manufacturing can improve government and hospital procurement positioning, but it does not automatically create reimbursement preference. Manufacturing operations must meet EU GMP requirements, and the supply chain must comply with serialization, GDP, pharmacovigilance and shortage-reporting rules.

The most defensible manufacturing positions are products with difficult synthesis, sterile production, device integration, controlled release, cold-chain logistics or limited qualified suppliers. Conventional immediate-release tablets have lower technical barriers and face faster price erosion.

What is the geographic coverage of Polish market authorization?

A Polish national authorization generally covers Poland. A decentralized or mutual-recognition procedure can provide access to several EU member states, while a centralized authorization can cover the EU and European Economic Area markets within the applicable regulatory framework.

A Polish manufacturing or commercial platform can therefore support regional expansion, but reimbursement, pricing, language, pharmacovigilance and tender rules remain national. A product’s Polish approval does not guarantee reimbursement or commercial launch in Germany, Czechia, Slovakia, Romania or the Baltic states.

How does Poland compare with other Central European markets?

Factor Poland Czech Republic Hungary Romania
Market scale Largest of the four Smaller, relatively structured Smaller, price-controlled Large population, reimbursement pressure
Generic penetration High High High High
Reimbursement control Strong Strong Strong Strong
Local manufacturing base Significant Moderate Significant Moderate
Tender exposure High in hospitals High High High
Regulatory route EU framework EU framework EU framework EU framework
Commercial challenge Price and reimbursement Reference pricing and access Price, taxes and tenders Payment and reimbursement execution

Poland’s scale is its main advantage. Its principal disadvantages are pricing pressure, administrative complexity, frequent reimbursement changes and high sensitivity to supply interruptions.

Key Takeaways

  • Poland is the leading pharmaceutical market in Central and Eastern Europe by scale.
  • Generics dominate prescription volume, while innovative products and biologics capture disproportionate value.
  • Market access depends on reimbursement-list inclusion, price negotiations, HTA and supply reliability.
  • Poland has no Paragraph IV pathway and no Orange Book.
  • Generic companies must assess EU regulatory exclusivity, European patents, Polish validation, SPCs and secondary patents.
  • Biosimilars have meaningful potential, especially in hospital oncology, immunology and diabetes.
  • Local manufacturing and reliable supply can improve commercial positioning but do not replace price competitiveness.
  • Patent litigation is product-specific and can involve formulation, manufacturing, device and method-of-use claims.
  • The strongest launch opportunities are complex generics, biosimilars, shortage-prone medicines and products with differentiated delivery systems.
  • The principal downside risks are price erosion, reimbursement delay, tender concentration, injunctions, payback exposure and supply obligations.

FAQs

Is a Polish marketing authorization enough to sell a generic across Europe?

No. A Polish authorization does not automatically authorize sale in all EU markets. Broader coverage requires a decentralized, mutual-recognition or centralized regulatory pathway, depending on the product.

Can a generic launch in Poland before a European patent expires?

Only if the product does not infringe a valid patent or SPC, or if a lawful exemption applies. Regulatory preparation may occur under the EU Bolar exemption, but commercial launch remains subject to enforceable rights.

Are Polish pharmacists allowed to substitute a generic for a branded medicine?

Substitution is permitted under Polish rules when the relevant product is therapeutically equivalent and applicable reimbursement and prescribing conditions are met. Commercial impact depends on the product category, prescription wording, patient choice and pharmacy economics.

Does Poland grant automatic reimbursement to EMA-approved medicines?

No. Marketing authorization and reimbursement are separate decisions. Reimbursement may require HTA, Ministry of Health negotiations, price commitments and inclusion in an official reimbursement announcement.

Which drug categories offer the best Polish market-entry prospects?

Complex generics, biosimilars, sterile injectables, hospital medicines, shortage-prone products, modified-release formulations and products with reliable local supply generally offer stronger opportunities than undifferentiated immediate-release tablets.

References

  1. IQVIA. (2024). The global use of medicines 2024: Outlook to 2028. IQVIA Institute for Human Data Science.

  2. European Parliament and Council. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use.

  3. Republic of Poland. (2011). Act of 12 May 2011 on the reimbursement of medicines, foodstuffs intended for particular nutritional uses and medical devices.

  4. European Commission. (2023). Pharmaceutical strategy for Europe and regulatory framework for medicinal products. European Commission.

  5. European Medicines Agency. (2019). Biosimilar medicines: Overview. EMA.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.